View of Pre-Targeting Bispecific Antibody (BSAB) and Pegylated Liposomal Drug Nanocarrier as Management of Acute Lymphoblastic Leukemia (ALL) In Pediatrics

Return to Article Details Pre-Targeting Bispecific Antibody (BSAB) and Pegylated Liposomal Drug Nanocarrier as Management of Acute Lymphoblastic Leukemia (ALL) In Pediatrics Download Download PDF